SOURCE: Cutting Edge Information

Cutting Edge Information

December 23, 2014 09:00 ET

Dedicated Patient-Reported Outcomes Teams Trending Among Large Pharmaceutical Companies

RESEARCH TRIANGLE PARK, NC--(Marketwired - December 23, 2014) - As patient-reported outcomes (PROs) become increasingly important to the clinical research process and to reimbursement discussions for pharmaceutical firms, more companies are building dedicated teams to shape PRO strategy and development. In a recent survey, pharmaceutical business intelligence provider Cutting Edge Information found that more than 50% of large and mid-sized companies now have dedicated PRO units, and other companies report that they are considering building a group.

Most surveyed companies house a dedicated patient-reported outcomes team under the larger umbrella of health economics and outcomes research. Strategy is then organized in a variety of ways, depending on the team's resources and goals. Teams typically organize their strategy by brand or therapeutic area, although global strategies are also developed. While it is not always feasible due to staffing limitations, the ideal alignment is by therapeutic area. This structure allows PRO teams to adapt to the unique demands of product profiles.

"Like many trends, this one is starting with the larger companies -- but soon could make its way to smaller firms," says David Richardson, Director of Research at Cutting Edge Information. "While many of the large and mid-sized pharmaceutical companies already have dedicated teams, surveyed small pharmaceutical companies have not yet begun adopting this structure."

"Patient-Reported Outcomes: Infusing the Healthcare Consumer Voice into Clinical Development and Reimbursement" reveals that maintaining a dedicated PRO team offers several advantages including focused attention and resources on PRO activities, scientific and strategic input to the clinical trial development process and regulatory compliance.

With the insights and metrics that this report provides, patient-reported outcomes and pharmacoeconomics executives will be prepared to demonstrate value to support implementing PROs to support regulatory and reimbursement initiatives. Other benefits of purchasing this study include:

  • Add PRO endpoints and measurements into clinical trials to add value to drug dossiers/payer discussions;
  • Develop and standardize in-house PRO development and implementation practices;
  • Determine best-fit PRO measurements as well as decide how many to use and how to leverage them in regulatory and reimbursement discussions;
  • Build and resource dedicated PRO teams; and
  • Understand emerging topics and trends in the PRO space, including the rise of ePRO technology and its impact on data quality.

To learn more about Cutting Edge Information's patient-reported outcomes research, please visit

Image Available:

Contact Information